Nikdokht Farid
In the rapidly evolving landscape of postsurgical, postradiation therapeutic strategies for patients with glioblastoma (GBM), including cytotoxic chemotherapy, antiangiogenic therapy, and immune therapy, bevacizumab has been established as a primary therapeutic option for recurrent GBM1,2 and has also shown substantial promise in the setting of newly diagnosed GBM.1,3 As a recombinant humanized monoclonal … more »
Dianne Daniels
Our group has previously introduced delayed-contrast MR imaging for calculating treatment-response-assessment maps (TRAMs) in patients with brain tumors undergoing standard treatments, providing a clear separation between an active tumor and treatment effects.1,2 Following this application of the TRAMs methodology to aid patient management and decision-making in patients with newly diagnosed high-grade glioma (HGG) … more »
Ilhami Kovanlikaya
Glioblastoma (GBM) is the most common aggressive primary brain tumor. Despite an aggressive multimodal treatment approach that includes surgical resection and chemoradiation, median survival is limited to approximately 14 months.1
Until recently, there was no standard treatment for recurrent disease after combined chemotherapy and radiation treatment. Between 1998 and 2014, there were 78 … more »
L. Celso Hygino da Cruz Jr.
After the institution of the current standard of care for high-grade gliomas, abnormal increase of the enhancing portion of the lesion was observed. According to the McDonald criteria, this could have represented recurrence. However, patients did not get clinically worse. In fact, this increase of the enhancing portion … more »
Whitney B. Pope
We published the first paper on bevacizumab-treated glioma over a decade ago and have since seen bevacizumab become an increasingly common, though controversial (as it does not seem to prolong survival), treatment for patients with glioma and other brain tumors. Given the large number of bevacizumab-treated patients in our neuro-oncology clinic, … more »
Benjamin M. Ellingson
High-grade gliomas including glioblastoma (GBM) have a terrible prognosis and survival has not changed appreciably in the last few decades. As a consequence of myriad failed trials, drug discovery in GBM has diminished extensively. Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor A (VEGFA), is one of only 3 … more »